Categories: News

EDWARDS LIFESCIENCES TO PRESENT AT THE 40TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

IRVINE, Calif., Jan. 5, 2022 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate at the J.P. Morgan Healthcare Conference on Monday, January 10, 2022. 

Michael A. Mussallem, chairman and chief executive officer, is scheduled to present virtually at 11:15 a.m. ET.  A live webcast of the presentation will be available to all interested parties on the Edwards Lifesciences investor relations website at http://ir.edwards.com/.  An archived version of the webcast will be available later that day on the Edwards’ investor relations website.

About Edwards Lifesciences
Edwards Lifesciences, is the global leader of patient-focused innovations for structural heart disease and critical care monitoring.  We are driven by a passion for patients, dedicated to improving and enhancing lives through partnerships with clinicians and stakeholders across the global healthcare landscape.  For more information, visit Edwards.com and follow us on Facebook, Instagram, LinkedIn, Twitter and YouTube.

Edwards, Edwards Lifesciences, and the stylized E logo are trademarks of Edwards Lifesciences Corporation.  All other trademarks are the property of their respective owners.

View original content to download multimedia:https://www.prnewswire.com/news-releases/edwards-lifesciences-to-present-at-the-40th-annual-jp-morgan-healthcare-conference-301454066.html

SOURCE Edwards Lifesciences Corporation

Staff

Recent Posts

cbdMD Announces Company’s CEO Joins the Board of Directors

Charlotte, North Carolina--(Newsfile Corp. - December 23, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE…

3 hours ago

Interactive Strength Inc. (Nasdaq: TRNR) Issues Year-End Update, Looks Ahead to 2025

AUSTIN, TEXAS / ACCESSWIRE / December 23, 2024 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or…

4 hours ago

Quest Diagnostics Upholds Strong Governance and Ethics With Robust Oversight, ESG Integration, and Comprehensive Risk Management

Originally published in Quest Diagnostics' 2023 Corporate Responsibility ReportNORTHAMPTON, MA / ACCESSWIRE / December 23,…

4 hours ago

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Marlborough, Massachusetts--(Newsfile Corp. - December 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage…

5 hours ago

ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…

7 hours ago

ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…

7 hours ago